The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in japanese patients undergoing major orthopedic surgery

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 109-113

  Hasegawa, Masahiro ^a   Wada, Hideo ^a   Wakabayashi, Hiroki ^a   Yoshida, Kakunoshin ^a   Miyamoto, Noriki ^a   Asanuma, Kunihiro ^a   Matsumoto, Takeshi ^a   Ohishi, Kohshi ^a   Shimokariya, Yuji ^a   Yamada, Norikazu ^a   Uchida, Atsumasa ^b   Sudo, Akihiro ^a  

^a Department of Orthopaedic Surgery ^*  (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti Xa activity; Deep vein thrombosis (DVT); Fondaparinux; Orthopedic surgery; Withdrawal

Indexed keywords

BIOLOGICAL MARKER; CREATININE; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FONDAPARINUX; HEMOGLOBIN; SOLUBLE FIBRIN; UNCLASSIFIED DRUG;

AGE; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; COMPRESSION THERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; FIBRINOGEN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

ANTI-XA ACTIVITY; DEEP VEIN THROMBOSIS (DVT); FONDAPARINUX; ORTHOPEDIC SURGERY; WITHDRAWAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; FACTOR XA; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84882983120     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.009     Document Type: Article

References (20)

1. Gehrie E., Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol 2012, 87:194-196.
2. Yoshida K., Wada H., Hasegawa M., et al. Monitoring for anti-Xa activity for prophylactic administration of fondaparinux in patients with artificial joint replacement. Int J Hematol 2011, 94:355-360.
3. Geerts W.H., Heit J.A., Clagett P., et al. Prevention of venous thromboembolism. Chest 2001, 119:S132-S175.
4. Piovella F., Wang C.J., Lu H., Rouillon A., et al. AIDA investigators: deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost 2005, 3:2664-2670.
5. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126:338S-400S.
6. Leclerc J.R., Gent M., Hirsh J., Geerts W.H., Ginsberg J.S. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1984 patients. Canadian Collaborative Group. Chest 1998, 114:115S-118S.
7. Colwell C.W., Collis D.K., Paulson R., et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg 1999, 81-A:932-940.
8. Heit J.A., Elliott C.G., Trowbridge A.A., Morrey B.F., Gent M., Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000, 132:853-861.
9. Bauersachs R.M. Fondaparinux: an update on new study results. Eur J Clin Invest 2005, 35:27-32.
10. Turpie A.G., Gallus A.S., Hoek J.A. Pentasaccharide investigators: a synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344:619-625.
11. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R. PENTATHALON 2000 study steering committee: postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359:1721-1726.
12. Yoshida Rde A., Yoshida W.B., Maffei F.H., El Dib R., Nunes R., Rollo H.A. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin. Ann Vasc Surg 2013, 27:355-369.
13. Beyer-Westendorf J., Lützner J., Donath L., et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. J Thromb Haemost 2012, 10:2045-2052.
14. Sasaki S., Miyakoshi N., Matsuura H., Saitoh H., Kudoh D., Shimada Y. Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. J Orthop Sci 2009, 14:491-496.
15. Yoshida K., Wada H., Hasegawa M., et al. Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux. Int J Hematol 2012, 95:160-166.
16. Teien A.N., Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977, 10:399-410.
17. van Putten J., van de Ruit M., Beunis M., Hemker H.C. Determination of low molecular weight heparin in clinical laboratory. Haemostasis 1984, 14:205-210.
18. Schellong S.M., Schwarz T., Halbritter K., et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 2003, 89:228-234.
19. Tsuji A., Wada H., Matsumoto T., et al. Elevated levels of soluble fibrin in patients with venous thromboembolism. Int J Hematol 2008, 88:448-453.
20. Niimi R., Hasegawa M., Shi D.Q., Sudo A. The influence of fondaparinux on the diagnosis of postoperative deep vein thrombosis by soluble fibrin and D-dimer. Thromb Res 2012, 130:759-764.